Sanara MedTech, Inc. (SMTI)

Sanara MedTech's stock price has experienced declines, with a 45.30% decrease from March 21, 2025, to March 20, 2026, and a 10.12% decrease in the past month as of March 21, 2026. Following its earnings release on January 23, 2026, the stock drifted 12.9% lower over the subsequent 59 days. A major strategic event was the discontinuation of its Tissue Health Plus (THP) value-based wound care program in mid-September 2025 due to persistent losses. In the fourth quarter of 2024, net revenue benefited from a one-time increase of approximately $1.8 million in BIASURGE sales. Sanara MedTech reported full-year 2025 net revenue of $103.1 million, a 19% increase year-over-year, and reaffirmed its full-year 2026 net revenue guidance of $116 million to $121 million. A peer-reviewed study published on March 11, 2026, evaluated the economic and clinical value of CellerateRX Surgical Powder in spine surgery wounds, reporting significant cost savings and clinical efficacy.

Based on 27 years of historical data, Sanara MedTech Inc. exhibits some seasonal tendencies, though with a "Poor" consistency score of 29.1. Historically, June tends to be the strongest month for the stock, with an average return of 55.32%. Conversely, November has historically been the weakest month, averaging a -10.56% return. Overall, the company has an average annual return of 139.19%.

Sanara MedTech, Inc. (SMTI) is a medical technology company focused on developing, marketing, and distributing technologies to improve clinical outcomes and reduce healthcare expenditures within the surgical market. The company operates in the Healthcare sector, specifically in the Medical Instruments & Supplies industry, with a product portfolio focused on surgical and chronic wound care, as well as skin care. Key products include surgical wound care products like CellerateRX Surgical Activated Collagen and chronic wound care products like HYCOL Hydrolyzed Collagen. The company is headquartered in Fort Worth, Texas, and was incorporated in 2001.

Sanara MedTech's products are primarily sold in the North American advanced wound care and surgical tissue repair markets, with a specific focus on the United States. The company has an expanding commercial footprint across the entire United States, with its products sold into over 1,450 healthcare facilities. They also leverage a growing network of independent distributor partners, which expanded to over 450 contracted partners by the end of 2025.

Sanara MedTech aims to be an innovative provider of effective surgical solutions, focused on developing and commercializing transformative technologies. The discontinuation of its Tissue Health Plus (THP) segment in September 2025 negatively impacted the company's reputation. A peer-reviewed study published on March 11, 2026, highlighted the economic and clinical value of CellerateRX Surgical Powder, which positively impacted the brand reputation.

Sanara MedTech's stock ownership is a mix of institutional, insider, and retail investors. Approximately 7.76% of the company's stock is owned by institutional investors, 2.80% by insiders, and 89.45% by public companies and individual investors. Major institutional owners include Baird Financial Group, Inc., BlackRock, Inc., and Vanguard Group Inc. Significant individual and insider owners include James W. Stuckert and S. Oden Howell Jr.